PGS testing cost depends on whether charges are billed per embryo or as a flat batch fee, combined with separate clinical biopsy and genetic laboratory analysis invoices. Because pricing structures differ between fertility clinics and independent reference laboratories, total expenses reflect biopsy procedure fees, lab screening charges, embryo freezing, ongoing storage, and subsequent frozen transfer preparation rather than a single unified charge.
Preimplantation genetic screening, historically termed PGS and now clinically referred to as PGT-A (preimplantation genetic testing for aneuploidy), evaluates embryos for normal chromosome counts before transfer. Because this service sits on top of standard in vitro fertilization, navigating the financial landscape requires understanding how clinic procedures, external genetic laboratories, and storage timelines interact.
Understanding the Split Billing Between Fertility Clinics and Genetics Labs
A common point of confusion for patients budgeting for embryo screening is that the procedure generates multiple invoices from entirely different entities. Your primary fertility clinic performs the ovarian stimulation, egg retrieval, fertilization, and embryonic culture. When embryos reach the blastocyst stage, your clinic embryologist carefully removes a small sample of cells from the trophectoderm, the outer layer destined to become the placenta. The clinic charges a technical biopsy fee for this delicate hands-on procedure, along with an initial cryopreservation fee to freeze the embryos while awaiting results.
The biopsied cellular samples are then placed in specialized preservation tubes and couriered to an independent genetic testing reference laboratory. This third-party lab processes the DNA, runs advanced sequencing panels to identify chromosomal duplications or deletions, and delivers the diagnostic report back to your reproductive endocrinologist. Consequently, you will receive a separate bill directly from the genetic testing company for the molecular analysis and courier handling. Understanding this dual-billing reality ensures you do not mistake a clinic biopsy quote for the total cost of screening.
Further reading: CDC: Assisted Reproductive Technology
Per-Embryo Fees Versus Tiered Batch Pricing Models
Genetics laboratories and fertility centers generally bill screening services using one of two fee structures: flat-rate tiered batching or individual per-embryo pricing. In a tiered batch model, the testing facility charges a set package price that covers screening up to a predetermined number of embryos, such as four, six, or eight samples from a single retrieval cycle. If your cycle yields fewer blastocysts than the package maximum, the total cost remains fixed. If your cycle yields more embryos than the tier allows, the lab bills an incremental add-on fee for each additional sample tested.
Conversely, per-embryo fee structures charge a base platform access fee alongside a distinct per-sample processing rate for every individual embryo submitted. This structure can be financially advantageous for patients expecting a modest number of blastocysts, as you avoid paying for unused testing capacity built into large package tiers. When gathering estimates, ask both your clinical coordinator and the contracted reference laboratory which pricing model governs your agreement and how unbiopsied or non-viable embryos affect the final invoice balance.
Hidden Secondary Costs: Cryopreservation, Storage, and Thaw Protocols
Opting for genetic screening fundamentally alters the timeline and logistical flow of an assisted reproduction cycle. Because genetic analysis takes days to weeks to yield conclusive results, fresh embryo transfers are generally not an option. Every embryo undergoing biopsy must be immediately vitrified (flash-frozen) and maintained in liquid nitrogen storage tanks while your clinical team awaits the chromosomal report.
These workflow adjustments introduce secondary expenses that may not appear on a preliminary testing quote. Clinics typically bill an initial cryopreservation fee covering the vitrification process and the first few months of storage. If your frozen transfer is delayed or if you undergo consecutive banking cycles before transferring, recurring long-term storage fees will accrue monthly or annually. Furthermore, preparing for a future frozen embryo transfer requires additional clinical appointments, baseline ultrasounds, hormonal monitoring, medication regimens, and laboratory thaw procedure fees.
Carefully evaluating these downstream procedural requirements helps prevent unexpected financial strain later in your family-building journey.
Further reading: CDC: Assisted Reproductive Technology
Clinical Criteria and When Testing Fits into Infertility Care
Deciding whether to add genetic screening involves clinical discussions with your reproductive endocrinologist about your specific diagnostic history, age, and reproductive goals. Formal clinical guidelines note that comprehensive infertility evaluations explore multiple physiological factors, including ovulatory function, uterine anatomy, tubal patency, and semen parameters. Within this broader diagnostic framework, genetic screening serves as an optional tool designed to select euploid (chromosomally normal) embryos, potentially reducing the time to a successful pregnancy by avoiding transfers of embryos with fatal aneuploidies.
However, genetic screening is not a therapeutic intervention that improves embryo quality; it is an observational screening test that classifies embryos already created. Patients producing very few embryos may discuss with their physician whether biopsy risks and laboratory costs align with their treatment strategy, as some individuals elect to transfer untested embryos rather than commit financial resources to laboratory analysis. Weighing personal medical history against out-of-pocket costs ensures that your diagnostic spending directly serves your clinical objectives.
Further reading: ACOG: Evaluating Infertility
Managing Screening Costs Across Multiple Embryo Banking Cycles
For patients planning multiple stimulation rounds—often called embryo banking—to collect several blastocysts before conducting a single transfer, screening logistics can significantly influence overall expenditures. Under standard billing rules, sending samples from three separate retrievals results in three distinct clinic biopsy setup charges and three separate lab courier and platform fees. This fragmented approach substantially increases your total testing investment.
To mitigate these compounding expenses, some genetics laboratories and clinic networks permit pooled or batched testing agreements. Under a batching protocol, your clinic biopsies and freezes embryos after each individual retrieval but holds the cellular biopsy samples in on-site cold storage until all planned cycles conclude. The clinic then ships the entire collection of samples to the genetics laboratory in a single parcel, allowing you to access higher-volume package discounts and pay only one transport and reporting fee. Verify whether your embryology lab supports sample holding and whether any administrative storage fees apply to delayed batch shipments.
Verifying Insurance Policies and Requesting Written Fee Disclosures
While standard medical insurance policies frequently exclude elective preimplantation screening, specific employer-sponsored fertility riders, state-mandated benefit plans, or health savings accounts (HSAs) and flexible spending accounts (FSAs) may cover components of the diagnostic workup. Because billing codes for the clinic biopsy differ from the molecular pathology codes used by the genetics lab, coverage may apply to one portion of the bill while completely excluding the other.
To establish an accurate financial forecast, contact both your fertility practice and the designated reference laboratory to request detailed, itemized Good Faith Estimates. Obtain the exact Current Procedural Terminology (CPT) diagnostic codes for the embryologist biopsy, the laboratory DNA amplification, and any accompanying frozen transfer preparation. Provide these specific billing codes to your insurance carrier to obtain binding written confirmation regarding deductible obligations, co-insurance percentages, and out-of-pocket maximum thresholds before starting your treatment protocol.
Frequently asked questions
Does insurance ever cover the cost of PGS or PGT-A testing?
Coverage varies widely depending on your specific policy benefits, employer plan design, and underlying medical indications. While elective screening is frequently considered an out-of-pocket elective expense, certain plans cover specific clinical components such as the embryologist biopsy or associated diagnostic bloodwork. Contact your insurer directly with itemized billing codes to verify specific benefit limitations before beginning treatment.
What happens financially if an embryo biopsy yields an inconclusive or no-result reading?
Occasionally, a cellular sample contains insufficient genetic material to produce a definitive chromosome readout. Most genetics testing companies have explicit re-testing policies that waive secondary laboratory analysis charges if a re-biopsy is submitted. However, your fertility clinic may still assess standard procedural fees for thawing, re-biopsying, and re-vitrifying the embryo, making it important to review clinic policies in advance.
Is embryo genetic screening mandatory for standard IVF cycles?
No, preimplantation genetic screening is entirely optional and is decided collaboratively between you and your reproductive endocrinologist. While many patients choose testing to prioritize transferring chromosomally balanced embryos, successful pregnancies routinely occur through untested fresh or frozen embryo transfers. Your physician can guide you on whether testing aligns with your specific clinical background.
Your next step
Contact your fertility clinic financial coordinator to request the exact legal name of their contracted genetics laboratory, then obtain itemized CPT billing codes from both entities to verify your total out-of-pocket costs with your insurance provider.